Skip to main content
Premium Trial:

Request an Annual Quote

Sciex, Singapore's PPC to Collaborate on Proteomic Cancer Biomarker Discovery

NEW YORK(GenomeWeb) – Sciex and the Protein and Proteomics Centre (PPC), under the National University of Singapore's department of biological sciences in the faculty of science, today announced the signing of a memorandum of understanding to promote joint R&D activities aimed at biomarker discovery and development. 

According to the partners, who will work with academic and industrial partners in biomedical research, the collaboration will lead to accelerated cancer detection and screening. 

Sciex, a Danaher company, and PPC will develop mass spectrometry-based methods for profiling proteins and metabolites found in zebrafish serum, and will cooperate to develop workshops on qualitative and quantitative proteomics to educate researchers in the Singapore region on alternative proteomic methods.

Approaches and technologies developed by researchers will be used for the discovery of cancer progression biomarkers in order to investigate the mechanisms, and pharmacokinetics and pharmacodynamics of anti-cancer drugs, as well as to detect biomarkers for environmental monitoring, Sciex and PPC said. 

PPC has three mass specs from Sciex to carry out the research, the QTRAP 6500, the TripleTOF 5600, and the 4800 Plus MALDI-TOF/TOF. It also has the Swath 2.0 Acquisition software to quantify protein biomarkers across large sample sets. 

"Our collaboration with PPC is another milestone that reflects our dedication to enabling Singapore-based researchers to find answers that will lead to new discoveries around disease pathways and drug development," Sciex President Jean-Paul Mangeolle said in a statement.